LG Chem eyes 2029 trials for personalized cancer vaccine

What happened: LG Chem said it aims to begin clinical development of a personalized mRNA cancer vaccine in 2029, using AI to speed drug discovery and identify patients most likely to benefit. Key numbers: Clinical development targeted for 2029; preclinical testing planned for 2027. Why it matters: LG Chem is building AI models to identify biomarkers that predict treatment responses and select patients for trials, which it describes as a key part of its precision oncology strategy.

LG Chem said it aims to begin clinical development of a personalized mRNA cancer vaccine in 2029, using AI to speed drug discovery and identify patients most likely to benefit.

LG Chem is building AI models to identify biomarkers that predict treatment responses and select patients for trials, which it describes as a key part of its precision oncology strategy.